Approach to the new oral anticoagulants in family practice: Part 2: Addressing frequently asked questions;Approche à l'égard des nouveaux anticoagulants oraux en pratique familiale: 2e partie : Répondre aux questions souvent posées

Canadian Family Physician

Volumn 60, Issue 11, 2014, Pages

  Douketis, James ^a   Bell, Alan David ^b   Eikelboom, John ^a   Liew, Aaron ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DABIGATRAN; HEPARIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RAMIPRIL; APIXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; AGED; ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING TEST; CASE REPORT; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; COLON POLYP; COLONOSCOPY; DEEP VEIN THROMBOSIS; DENTAL PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHROCYTE TRANSFUSION; FLUID THERAPY; FOLLOW UP; GASTROINTESTINAL CLIP; GENERAL PRACTICE; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LONG TERM CARE; MALE; MALIGNANT NEOPLASTIC DISEASE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POLYPECTOMY; PREOPERATIVE EVALUATION; PRIMARY MEDICAL CARE; REVIEW; SUPERFICIAL THROMBOPHLEBITIS; SURGICAL RISK; VALVULAR HEART DISEASE; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMPLICATION; HEMORRHAGE; ORAL DRUG ADMINISTRATION; PREOPERATIVE CARE; STROKE; TIME;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DABIGATRAN; FAMILY PRACTICE; HEMORRHAGE; HUMANS; MORPHOLINES; PREOPERATIVE CARE; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE; THIOPHENES; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84911366554     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Pradaxa [product monograph]. Burlington, ON: Boehringer Ingelheim Canada;2012.
2. Xarelto [product monograph]. Toronto, ON: Bayer Inc;2013.
3. Eliquis [product monograph]. Montreal, QC: Bristol-Myers Squibb;2012.
4. Skanes AC, Healey JS, Cairns JA, Dorian P, Gillia AM, McMurtry MS, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28(2):125-36.
5. Douketis J, Bell AD, Eikelboom J, Liew A. Approach to the new oral anticoagulants in family practice. Part 1: comparing the options. Can Fam Physician 2014;60:989-95 (Eng), e504-11 (Fr).
6. Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol 2013;11(3):246-52.
7. Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 2013;51(7):549-61.
8. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosequeda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013;75(2):476-87.
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51.
10. Erratum in: N Engl J Med 2010;363(19):1877.
11. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91.
12. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92.
13. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46(5):549-58.
14. Moore KT, Plotnikov AN, Thyssen A, Vaccaro N, Ariyawansa J, Burton PB. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol 2011;58(6):581-8.
15. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45(5):555-63.
16. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e44S-88S.
17. Friedman RJ, Kurth A, Clemens A, Noack H, Eriksson BI, Caprini JA. Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding. Thromb Haemost 2012;108(1):183-90.
18. Eriksson BI, Rosencher N, Friedman RJ, Homering M, Dahl OE. Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thromb Res 2012;130(2):147-51.
19. Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-Analysis. Eur Heart J 2013;34(22):1670-80.
20. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Delborg M, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119(22):2877-85.
21. Mega JL, Braunwald E, Murphy SA, Plitnikov AN, Burton P, Kiss RG, et al. Rivaroxaban in patients stabilized after a ST-elevation myocardial infarction: results from the ATLAS ACS 2-TIMI 51 trial. J Am Coll Cardiol 2013;61(18):1853-9.
22. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366(1):9-19.
23. Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des 2010;16(31):3436-41.
24. Alikhan R, Rayment R, Keeling D, Baglin T, Benson G, Green L, et al. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J 2013;31(2):163-8.
25. Thrombosis Canada [website]. Clinical guides. Hamilton, ON: Thrombosis Canada. Available from: http://thrombosiscanada.ca/?page-id=18. Accessed 2014 Sep 23.
26. Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation 2012;126(20):2428-32.
27. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012;126(3):343-8.
28. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103(6):1116-27.
29. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban-An oral, direct factor Xa inhibitor. Thromb Haemost 2010;103(4):815-25.
30. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol 2010;85(3):185-7.
31. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010;104(6):1263-71.
32. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23(2):138-43.
33. Mani H, Rohde G, Stratmann G, Hesse C, Herth N, Schwers S, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 2012;108(1):191-8.
34. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012;107(2):379-87.
35. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 2013;34(7):489-98b.
36. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124(14):1573-9.
37. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012;108(2):217-24.
38. Dowlatshahi D, Butcher KS, Asdaghi N, Nahirniak S, Bernbaum ML, Giulivi A, et al. Poor prognosis in warfarin-Associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012;43(7):1812-7.
39. Marrone LC, Marrone AC. Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report. Cerebrovasc Dis 2012;34(3):246-7.
40. De Smedt A, De Raedt S, Nieboer K, De Keyser J, Brouns R. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 2010;30(5):533-4.
41. Takeuchi S, Wada K, Nagatani K, Otani N, Osada H, Nawashiro H. Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients. Acta Neurochir (Wien) 2012;154(1):87.
42. Casado Naranjo I, Portilla-Cuenca JC, Jimenez Caballero PE, Calle Escobar ML, Romero Sevilla RM. Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran. Cerebrovasc Dis 2011;32(6):614-5.
43. Matute MC, Guillan M, Garcia-Caldentey J, Buisan J, Aparicio M, Masjuan J, et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011;106(1):178-9.
44. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest 2012;141(2 Suppl):e576S-600S.
45. Price J, Hynes M, Labinaz M, Ruel M, Boodhwani M. Mechanical valve thrombosis with dabigatran. J Am Coll Cardiol 2012;60(17):1710-1.
46. Van de Werf F, Brueckmann M, Connolly SJ, Friedman J. Granger CB, Hartter S, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement (RE-ALIGN). Am Heart J 2012;163(6):931-7.e1.
47. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Holdhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl): e419S-94S.
48. Erratum in: Chest 2012;142(6):1698-704.